• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Rapid Micro Biosystems Inc.

    2/28/25 4:54:54 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RPID alert in real time by email
    S-8 1 rpid_s-8xq1x2025.htm S-8 Document

    As filed with the Securities and Exchange Commission on February 28, 2025
    Registration No. 333-
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
     
    FORM S-8
    REGISTRATION STATEMENT
    Under the Securities Act of 1933
     
     
     
    Rapid Micro Biosystems, Inc.
    (Exact name of registrant as specified in its charter)
     
     
     
    Delaware 20-8121647
    (State or other jurisdiction of
    incorporation or organization)
     
     
    (IRS Employer
    Identification No.)
     
    25 Hartwell Avenue
    Lexington, MA
    02421
    (Address of principal executive offices)(Zip code)

     
    Rapid Micro Biosystems, Inc. 2021 Incentive Award Plan
    Rapid Micro Biosystems, Inc. 2021 Employee Stock Purchase Plan
    Rapid Micro Biosystems, Inc. 2023 Inducement Plan
    (Full title of the plan)

     

    Robert Spignesi
    President and Chief Executive Officer
    Rapid Micro Biosystems, Inc.
    25 Hartwell Avenue
    Lexington, MA 02421
    (Name and address of agent for service)

    (978) 349-3200
    (Telephone number, including area code, of agent for service)

     
    Copy to:
    Edwin O'Connor, Esq.
    Adam Johnson, Esq.
    Goodwin Procter LLP
    620 Eighth Avenue
    New York, NY 10018
    (212) 813-8800
     
     



     
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
           
    Large accelerated filer ¨ Accelerated filer ¨
        
    Non-accelerated filer x Smaller reporting company x
        
        Emerging growth company x
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
     





    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by Rapid Micro Biosystems, Inc. (the “Registrant”) for the purpose of registering (i) 1,886,462 additional shares of Class A common stock, par value $0.01 per share (“Common Stock”), under the Registrant’s 2021 Incentive Award Plan (the “2021 Plan”), which were added on January 1, 2025 as a result of an automatic annual increase provision therein and (ii) 377,292 additional shares of Common Stock under the Registrant’s 2021 Employee Stock Purchase Plan (the “ESPP”), which were added on January 1, 2025 as a result of an automatic annual increase provision therein.

    This Registration Statement also registers 476,000 additional shares of Common Stock under the Registrant’s 2023 Inducement Plan, as amended by the Second Amendment to the Inducement Plan (as amended, the “Inducement Plan”), pursuant to which the aggregate number of shares of Common Stock reserved and available for issuance under the Inducement Plan was increased by 476,000 shares.

    All of the additional shares of Common Stock registered on this Registration Statement are of the same class as other securities for which a registration statement is effective. This Registration Statement is being filed for the purpose of increasing the number of shares of Common Stock issuable pursuant to the 2021 Plan, ESPP and Inducement Plan, and re-registering shares of Common Stock underlying forfeited restricted stock units previously granted under the 2021 Plan and the Inducement Plan. The Registrant’s registration statements on Form S-8 filed on July 16, 2021 (File No. 333-257981), relating to the 2021 Plan and the ESPP, and on May 4, 2023 (File No. 333-271659), relating to the Inducement Plan, are hereby incorporated by reference pursuant to General Instruction E.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information called for in Part I of Form S-8 is not being filed with or included in this Registration Statement (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”).

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3.Incorporation of Documents by Reference.
     
    The following documents, which have been filed with the Commission by the Registrant, pursuant to the Securities Act of 1933, as amended (the “Securities Act”), and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as applicable, are hereby incorporated by reference in, and shall be deemed to be a part of, this Registration Statement:
     
    (a)    The Registrant’s Annual Report on Form 10-K for its fiscal year ended December 31, 2024, filed with the Commission on February 28, 2025 (Commission File No. 001-40592).
     
    (b)    The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-40592) filed with the Commission on July 12, 2021, including any amendments or reports filed for the purpose of updating such description, including Exhibit 4.7 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the Commission on March 1, 2024. 

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all such securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents.
     



    Any statement contained in this Registration Statement, in an amendment hereto or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed amendment to this Registration Statement or in any document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement, except as to such specific section of such statements as set forth therein.

    Item 4.Description of Securities.
    Not applicable.

    Item 5.Interests of Named Experts and Counsel.
    Not applicable.

    Item 6.Indemnification of Directors and Officers.
    The following summary is qualified in its entirety by reference to the complete copy of the Delaware General Corporation Law (the “DGCL”) and the Registrant’s Restated Certificate of Incorporation and Amended and Restated Bylaws.

    Section 102 of the DGCL permits a corporation to eliminate or limit the personal liability of directors to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. The Registrant’s Restated Certificate of Incorporation provides that no director of the Registrant shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.

    Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

    The Registrant’s Amended and Restated Bylaws provide that the Registrant will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of it) by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at the Registrant’s request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an “Indemnitee”), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the Registrant’s best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. The Registrant’s Amended and Restated Bylaws



    provide that the Registrant will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of the Registrant to procure a judgment in the Registrant’s favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at the Registrant’s request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the Registrant’s best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the Registrant, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by the Registrant against all expenses (including attorneys’ fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances.

    The Registrant has entered into indemnification agreements with each of the Registrant’s directors and executive officers. These indemnification agreements may require the Registrant, among other things, to indemnify its directors and executive officers for some expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of his or her service as one of the Registrant’s directors or executive officers, or any other company or enterprise to which the person provides services at the Registrant’s request.

    The Registrant maintains a general liability insurance policy that covers certain liabilities of directors and officers of the Registrant’s corporation arising out of claims based on acts or omissions in their capacities as directors or officers.

    Item 7.Exemption from Registration Claimed.

    Not applicable.


    Item 8.Exhibits.

    Exhibit Number
     Description of Exhibit
      
    4.1
     
    Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant's Annual Report on Form 10-K (File No. 001-40952) filed on February 28, 2025).
       
    4.2
     
    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K (File No. 001-40952) filed on July 21, 2021).
      
    5.1+
     
    Opinion of Goodwin Procter LLP.
    23.1+
     
    Consent of PricewaterhouseCoopers LLP.
      
    23.2+
     
    Consent of Goodwin Procter LLP (included in Exhibit 5.1).
      
    24.1
     
    Power of Attorney (included on signature page).
      



    99.1
    Rapid Micro Biosystems, Inc. 2021 Incentive Award Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.2 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on July 12, 2021).
    99.2
    Rapid Micro Biosystems, Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on July 12, 2021).
    99.3
    Rapid Micro Biosystems, Inc. 2023 Inducement Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 99.1 to the Registrant’s Registration Statement on Form S-8 (File No. 333-271659) filed on May 4, 2023).
    99.4
    First Amendment to Rapid Micro Biosystems, Inc. 2023 Inducement Plan (incorporated by reference to Exhibit 10.21 to the Registrant’s Annual Report on Form 10-K (File No. 001-40952) filed on March 1, 2024).
    99.5
    Second Amendment to Rapid Micro Biosystems, Inc. 2023 Inducement Plan (incorporated by reference to Exhibit 10.21 to the Registrant’s Annual Report on Form 10-K (File No. 001-40952) filed on February 28, 2025).
    107+
     
    Fee Filing Table.
     
     
    + Filed herewith



    Item 9.Undertakings.
     
    (a) The undersigned Registrant hereby undertakes:
     
    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
     
    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
     
    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and
     
    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;
     
    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.
     



    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and
     
    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
     
    (b)    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
     
    (h)    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.




    SIGNATURES
     
    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lexington, Commonwealth of Massachusetts, on the 28th day of February, 2025.
     RAPID MICRO BIOSYSTEMS, INC.
     
     By:/s/ Robert Spignesi  
      Robert Spignesi
      President and Chief Executive Officer
    POWER OF ATTORNEY

    We, the undersigned officers and directors of Rapid Micro Biosystems, Inc., hereby severally constitute and appoint Robert Spignesi and Sean Wirtjes, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement (or any other registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities held on the dates indicated.

    Signature Title Date
    /s/ Robert Spignesi   President, Chief Executive Officer and Director (principal executive officer) February 28, 2025
    Robert Spignesi
    /s/ Sean Wirtjes Chief Financial Officer (principal financial officer and principal accounting officer) February 28, 2025
    Sean Wirtjes
    /s/ Kirk D. Malloy  Chair of the Board of Directors February 28, 2025
    Kirk D. Malloy, Ph.D.
    /s/ Richard Kollender   Director February 28, 2025
    Richard Kollender
    /s/ Melinda Litherland Director February 28, 2025
    Melinda Litherland   
        
    /s/ Inese Lowenstein Director February 28, 2025
    Inese Lowenstein   

        
    /s/ Natale Ricciardi Director February 28, 2025
    Natale Ricciardi   
    /s/ Jeffrey SchwartzDirectorFebruary 28, 2025
    Jeffrey Schwartz

    Get the next $RPID alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RPID

    DatePrice TargetRatingAnalyst
    2/12/2025$8.00Overweight
    KeyBanc Capital Markets
    8/16/2022Overweight → Neutral
    JP Morgan
    3/7/2022$11.00 → $10.00Equal-Weight
    Morgan Stanley
    2/15/2022$24.00 → $11.00Equal-Weight
    Morgan Stanley
    11/15/2021$26.00 → $24.00Equal-Weight
    Morgan Stanley
    8/9/2021Outperform
    Cowen
    8/9/2021$26.00Equal-Weight
    Morgan Stanley
    8/9/2021$28.00Buy
    Stifel
    More analyst ratings

    $RPID
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rapid Micro Biosystems Reports First Quarter 2025 Financial Results

      Reports first quarter 2025 total revenue of $7.2 million, representing 28% growth compared to the first quarter of 2024. Reports record quarterly service revenue led by strong validation activity. Reports first quarter gross margin of 6%, representing a 33-percentage point improvement compared to the first quarter of 2024.Announced a global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany, which operates in the U.S. as MilliporeSigma ("MilliporeSigma"). Reaffirms full-year 2025 total revenue guidance of at least $32.0 million. LEXINGTON, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Compa

      5/9/25 7:00:55 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems to Announce First Quarter 2025 Financial Results on May 9, 2025

      LEXINGTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2025 financial results prior to the market open on Friday, May 9, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, May 9, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and available for replay after

      4/24/25 4:15:32 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grants (i) on March 3, 2025, of 50,000 restricted stock units ("RSUs") of the Company's Class A common stock ("Common Stock") as a material inducement to employment of one new employee and (ii) on March 10, 2025, of non-qualified stock options to purchase an aggregate of 250,000 shares of Common Stock (the "Options") and 174,000 RSUs as a material inducement to employment to two

      3/12/25 4:30:02 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    SEC Filings

    See more
    • SEC Form 10-Q filed by Rapid Micro Biosystems Inc.

      10-Q - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)

      5/9/25 4:21:23 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)

      5/9/25 7:06:07 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Rapid Micro Biosystems Inc.

      DEFA14A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)

      4/8/25 4:53:08 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT AND CEO Spignesi Robert G. Jr. covered exercise/tax liability with 10,650 shares, decreasing direct ownership by 1% to 872,366 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      3/11/25 7:19:38 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • CHIEF FINANCIAL OFFICER Wirtjes Sean M covered exercise/tax liability with 7,690 shares, decreasing direct ownership by 2% to 489,955 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      3/11/25 7:18:44 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • CHIEF OPERATING OFFICER Wilson John J. Addington covered exercise/tax liability with 9,872 shares, decreasing direct ownership by 4% to 232,474 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      3/11/25 7:17:20 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Financials

    Live finance-specific insights

    See more
    • Rapid Micro Biosystems Reports First Quarter 2025 Financial Results

      Reports first quarter 2025 total revenue of $7.2 million, representing 28% growth compared to the first quarter of 2024. Reports record quarterly service revenue led by strong validation activity. Reports first quarter gross margin of 6%, representing a 33-percentage point improvement compared to the first quarter of 2024.Announced a global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany, which operates in the U.S. as MilliporeSigma ("MilliporeSigma"). Reaffirms full-year 2025 total revenue guidance of at least $32.0 million. LEXINGTON, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Compa

      5/9/25 7:00:55 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems to Announce First Quarter 2025 Financial Results on May 9, 2025

      LEXINGTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2025 financial results prior to the market open on Friday, May 9, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, May 9, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and available for replay after

      4/24/25 4:15:32 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance

      Reports record fourth quarter 2024 total revenue of $8.2 million, representing 30% growth compared to fourth quarter 2023; recurring revenue increased by 27% compared to the fourth quarter of 2023.Announces full year 2024 total revenue of $28.1 million, representing 25% growth compared to 2023; recurring revenue increase by 14% compared to 2023.Reports record fourth quarter gross margin of 12%, representing a 15-percentage point improvement over the fourth quarter of 2023; full year 2024 gross margin increased 24 percentage points compared to 2023.Announces global Distribution and Collaboration Agreement with MilliporeSigma LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Rapid Micro

      2/28/25 6:30:13 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Leadership Updates

    Live Leadership Updates

    See more
    • Rapid Micro Biosystems Announces Appointment of Kirk Malloy, Ph.D. as Chair of its Board of Directors

      LOWELL, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Kirk Malloy, Ph.D. as Chair of the Company's Board of Directors (the "Board"). Dr. Malloy will also Chair the Board's Compensation Committee. Jeffrey Schwartz, who previously served as Board Chair, remains a member of the Board and continues to serve as Chair of the Nominating and Corporate Governance Committee. "We are very excited to welcome Kirk to our Boar

      7/18/23 5:20:56 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems Announces the Appointment of Michael Wysocki as Senior Vice President, Sales and Marketing

      LOWELL, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Michael Wysocki to the position of Senior Vice President, Sales and Marketing. Wysocki joins the Company with nearly two decades of experience at General Electric and GE Healthcare. During his GE career, he held roles of increasing responsibility in their imaging, molecular imaging and computed tomography (CT) businesses before becoming the General Manager, U.S

      5/4/23 4:30:10 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Reaction Biology Announces Appointment of Richard S. Kollender to Chief Financial Officer and Chief Business Officer

      MALVERN, Pa., April 4, 2022 /PRNewswire/ -- Reaction Biology ("Reaction" or the "Company"), an industry-leading provider of drug discovery services, today announced the appointment of Richard S. Kollender to the positions of Chief Financial Officer (CFO), Chief Business Officer (CBO) and member of the Executive Committee, effective immediately, to further strengthen the leadership team and support the Company's next stage of growth. "We are thrilled to welcome Rich, a seasoned healthcare finance and operations executive, to the Executive Committee of Reaction Biology," said John H. Johnson, Chief Executive Officer and Director of Reaction Biology.  "Having managed large, global biopharmaceut

      4/4/22 9:30:00 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • KeyBanc Capital Markets initiated coverage on Rapid Micro Biosystems with a new price target

      KeyBanc Capital Markets initiated coverage of Rapid Micro Biosystems with a rating of Overweight and set a new price target of $8.00

      2/12/25 7:09:40 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Rapid Micro Biosystems downgraded by JP Morgan

      JP Morgan downgraded Rapid Micro Biosystems from Overweight to Neutral

      8/16/22 7:57:15 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Morgan Stanley reiterated coverage on Rapid Micro Biosystems with a new price target

      Morgan Stanley reiterated coverage of Rapid Micro Biosystems with a rating of Equal-Weight and set a new price target of $10.00 from $11.00 previously

      3/7/22 8:37:27 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

      SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

      2/14/24 10:04:40 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

      SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

      1/22/24 5:28:26 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

      SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

      2/14/23 4:17:23 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RPID
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Pei Melinda Litherland bought $20,364 worth of shares (20,000 units at $1.02), increasing direct ownership by 58% to 54,300 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      12/5/24 6:44:47 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Pei Melinda Litherland bought $20,999 worth of shares (20,000 units at $1.05), increasing direct ownership by 140% to 34,300 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      11/27/24 9:42:03 PM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Malloy Kirk bought $45,335 worth of shares (50,000 units at $0.91), increasing direct ownership by 350% to 64,300 units (SEC Form 4)

      4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

      8/9/24 8:36:24 AM ET
      $RPID
      Biotechnology: Laboratory Analytical Instruments
      Industrials